Kinase inhibition in autoimmunity and inflammation
AA Zarrin, K Bao, P Lupardus, D Vucic - Nature Reviews Drug …, 2021 - nature.com
Despite recent advances in the treatment of autoimmune and inflammatory diseases, unmet
medical needs in some areas still exist. One of the main therapeutic approaches to alleviate …
medical needs in some areas still exist. One of the main therapeutic approaches to alleviate …
State-of-the-art evidence in the treatment of systemic sclerosis
JE Pope, CP Denton, SR Johnson… - Nature Reviews …, 2023 - nature.com
Systemic sclerosis (SSc) is a rare autoimmune connective tissue disease with multi-organ
involvement, fibrosis and vasculopathy. Treatment in SSc, including early diffuse cutaneous …
involvement, fibrosis and vasculopathy. Treatment in SSc, including early diffuse cutaneous …
Systemic sclerosis-associated interstitial lung disease
A Perelas, RM Silver, AV Arrossi… - The Lancet respiratory …, 2020 - thelancet.com
Systemic sclerosis is an autoimmune connective tissue disease, which is characterised by
immune dysregulation and progressive fibrosis that typically affects the skin, with variable …
immune dysregulation and progressive fibrosis that typically affects the skin, with variable …
Progressive pulmonary fibrosis: an expert group consensus statement
This expert group consensus statement emphasises the need for standardising the definition
of progressive fibrosing interstitial lung diseases (F-ILDs), with an accurate initial diagnosis …
of progressive fibrosing interstitial lung diseases (F-ILDs), with an accurate initial diagnosis …
Systemic sclerosis–associated interstitial lung disease: How to incorporate two food and drug administration–approved therapies in clinical practice
Systemic sclerosis (SSc; scleroderma) has the highest individual mortality of all rheumatic
diseases, and interstitial lung disease (ILD) is among the leading causes of SSc‐related …
diseases, and interstitial lung disease (ILD) is among the leading causes of SSc‐related …
Interstitial lung disease associated with systemic sclerosis (SSc-ILD)
V Cottin, KK Brown - Respiratory research, 2019 - Springer
Abstract Background Systemic sclerosis (SSc) is a rare connective tissue disease with a
heterogeneous clinical course. Interstitial lung disease (ILD) is a common manifestation of …
heterogeneous clinical course. Interstitial lung disease (ILD) is a common manifestation of …
Pirfenidone: molecular mechanisms and potential clinical applications in lung disease
SM Ruwanpura, BJ Thomas… - American journal of …, 2020 - atsjournals.org
Pirfenidone (PFD) is a pharmacological compound with therapeutic efficacy in idiopathic
pulmonary fibrosis. It has been chiefly characterized as an antifibrotic agent, although it was …
pulmonary fibrosis. It has been chiefly characterized as an antifibrotic agent, although it was …
Treatment of systemic sclerosis–associated interstitial lung disease: evidence-based recommendations. An official American Thoracic Society clinical practice …
G Raghu, SB Montesi, RM Silver, T Hossain… - American journal of …, 2024 - atsjournals.org
Background: Interstitial lung disease (ILD) is a significant cause of morbidity and mortality in
patients with systemic sclerosis (SSc). To date, clinical practice guidelines regarding …
patients with systemic sclerosis (SSc). To date, clinical practice guidelines regarding …
Systemic sclerosis
CP Denton, D Khanna - The Lancet, 2017 - thelancet.com
Systemic sclerosis, also called scleroderma, is an immune-mediated rheumatic disease that
is characterised by fibrosis of the skin and internal organs and vasculopathy. Although …
is characterised by fibrosis of the skin and internal organs and vasculopathy. Although …
[HTML][HTML] Pirfenidone safety and adverse event management in idiopathic pulmonary fibrosis
LH Lancaster, JA de Andrade, JD Zibrak… - European respiratory …, 2017 - Eur Respiratory Soc
Pirfenidone is one of two approved therapies for the treatment of idiopathic pulmonary
fibrosis (IPF). Randomised controlled clinical trials and subsequent post hoc analyses have …
fibrosis (IPF). Randomised controlled clinical trials and subsequent post hoc analyses have …